Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia.

Slides:



Advertisements
Similar presentations
Cardiovascular Side Effects of HIV Treatment
Advertisements

Aging, Inflammation, and Organ Damage in HIV+ Patients Jean-Pierre Routy, MD Graeme Moyle, MD Bill Powderly, MD Philippe Morlat, MD.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Aggressive Hyperglycemia Management. Significant hospital hyperglycemia requires close follow-up Previously diagnosed diabetes and elevated A1C Without.
Key messages Stephen S Lim, et al. Lancet 2007; 370:
Slide 1 of 11 From CB Hicks, MD, at Chicago, IL: May 20, 2013, IAS-USA. IAS–USA Charles B. Hicks, MD Professor of Medicine Duke University Medical Center.
Chronic diseases in HIV Francois Venter Wits Reproductive Health & HIV Institute
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) The LIPID Study Group N Engl J Med 1998;339:
Kuala Lumpur, Malaysia, 30 June - 3 July 2013 Abstract: WEABO205. HIV infection was associated with an increased risk of hip fracture,
Dr Verity Blackwell West Hertfordshire Dermatology Team.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2010.
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
The concept of Diabetes & CV risk: A lifetime risk challenge
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
NCD Complications in HIV Patients Esteban Martinez Hospital Clínic University of Barcelona Barcelona SPAIN Washington D.C., USA,
HIV Early Treatment Project Groups 1 and 2 n Among HIV-infected participants in sub-Saharan Africa, does initiation of antiretroviral treatment (ART) at.
ACCORD - Action to Control Cardiovascular Risk in Diabetes ADVANCE - Action in Diabetes to Prevent Vascular Disease VADT - Veterans Administration Diabetes.
Risk of serious disease and death in people with HIV viral suppression on ART: an epidemiologic perspective The Lancet and Cell Meeting What Will it Take.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
Global impact of ischemic heart disease World Heart Federation, 2011.
Emily O’Brien, Emil Fosbol, Andrew Peng, Karen Alexander, Matthew Roe, Eric Peterson The Obesity Paradox: The Importance for Long-term Outcomes in Non-ST-Elevation.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
1FHI 360 Nigeria. 2USAID Nigeria
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Wafaa El-Sadr, MD, MPH ICAP-Columbia University The World Before SMART.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
M Mohsen Ibrahim, MD CARDIOLOGY DEPARTMENT-CAIRO UNIVERSITY MINIMAL vs OPTIMAL MEDICAL CARE.
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Modern Management of Cholesterol in the High-Risk Patient.
Aging and Cardiovascular Disease Marek Smieja, MD PhD FRCPC.
HIV and serious non-AIDS conditions Five Years after the SMART Study, a Paradigm Shifting Trial INSIGHT Symposium XIX International AIDS Conference Washington.
FDA Endocrinologic and Metabolic Drugs Advisory Committee 1st June 2008 Rury Holman Clinical outcomes with anti-diabetic drugs: What we already know.
Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Introductory talk D Costagliola.
WOSCOPS: West Of Scotland Coronary Prevention Study Purpose To determine whether pravastatin reduces combined incidence of nonfatal MI and death due to.
The role of treatment versus disease in causing premature non-AIDS morbidity Judith S. Currier, MD University of California, Los Angeles.
Lancet 373: , 2009 Baseline Characteristics of Participants and Study Design of Clinical Trials to Compare Intensive glucose- lowering versus.
AA-2-1 Jerome D. Cohen, MD, FACC, FACP Professor of Internal Medicine / Cardiology Director, Preventive Cardiology Programs St. Louis University Health.
Prevention of Diabetes Mellitus Prof. Adel El-Etriby Professor of Cardiology Ain Shams Faculty of Medicine.
Individualization Strategies for Older Patients with Diabetes Elbert S. Huang, MD MPH FACP University of Chicago.
Evidence for the link between markers of inflammation, coagulation and immune activation and end organ disease Session: Immune Activation/Inflammation.
Innovations in Management of Cardiovascular Disease for Global Health
Describing the risk of an event and identifying risk factors Caroline Sabin Professor of Medical Statistics and Epidemiology, Research Department of Infection.
The Obesity/Diabetes Epidemic: Perspectives, Consequences, Prevention, Treatment Stan Schwartz MD, FACP, FACE Private Practice, Ardmore Obesity Program.
HIV infection and cardiovascular diseases Matthew S. Freiberg, MD, MSc University of Pittsburgh School of Medicine and Graduate School of Public Health.
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.
Can early antiretroviral therapy fully restore health? Workshop on Pathogeneses and Management of Long-Term Complications of ART IAS Conference, Rome July.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Fat or Low-fat? Anwar T. Merchant ScD, MPH, DMD Department of Epidemiology and Biostatistics.
Assessment of cardiovascular risk in a 3-year- cohort of HIV-infected patients of Sub-Saharan origin living in France or Côte d’Ivoire and starting antiretroviral.
Acute Renal Failure in HIV- Infected Individuals Greatly Increases Risk for In-Hospital Mortality Slideset on: Wyatt CM, Arons RR, Klotman PE, Klotman.
Linkages between CDs & NCDs: The African context Dr Frank J Mwangemi ICASA 2011: 5 th December 2011 Addis Ababa, Ethiopia.
Problems of HIV Infection in the HAART Era Akihiko Suganuma M.D. Tokyo Metropolitan Komagome Hospital Department of Infectious Diseases.
Case 1: Elevated LDL-C in a Young Adult. Page 2 of 10 *DALY; disability-adjusted life years Routine checkup:  Age:33 years  Sex: male  Status: Except.
Slideset on: Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving.
Antonio Coca, MD, PhD, FRCP, FESC
Alcohol, Other Drugs, and Health: Current Evidence July–August 2017
Copyright © 2007 American Medical Association. All rights reserved.
The Anglo Scandinavian Cardiac Outcomes Trial
Lipid-Lowering Arm (ASCOT-LLA): Results in the Subgroup of Patients with Diabetes Peter S. Sever, Bjorn Dahlöf, Neil Poulter, Hans Wedel, for the.
Goals & Guidelines A summary of international guidelines for CHD
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Presentation transcript:

Cardiovascular Complications of HIV Mark Boyd MD, FRACP The Kirby Institute for infection and immunity in society 7 th IAS Conference Kuala Lumpur, Malaysia 03 July 2013

Cardiovascular Complications of HIV Conflicts of interest GrantsHonorariaAbbVie Gilead SciencesBoehringer-Ingelheim MerckBristol Myers Squibb Janssen-Cilag Merck

Cardiovascular Complications of HIV Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Cardiovascular Complications of HIV Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Myocardial Infarction rates in HIV+ versus HIV- Triant J, et al. Clin Endocrinol Metab Mean MI rate = 11 v 7 per 1000 person years RR=1.7

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Risk factors CVD HIV+ vs HIV- Kaplan R, et al. CID Dyslipidaemia Smoking Insulin resistance HIV-neg men HIV-pos men HIV-neg women HIV-pos. women

Comorbidity distribution * Schouten J et al. World AIDS Conference July 2012; updated May 2013 (personal communication, Reiss P)

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

SMART - major CVD, hepatic or renal disease No. of patients with events Endpoints Major CVD, hepatic or renal disease 104 CVD, fatal or non-fatal79 Favours VS ► ► Favours DC Relative risk (95% CI) Renal disease, fatal or non-fatal Hepatic disease, fatal or non-fatal El-Sadr W, et al. SMART. NEJM 2006

Cardiovascular complications of HIV SMART: risk of death strongly associated with IL-6 & D-dimer biomarker levels at study entry Biomarker<25 th percentile (reference) 25 th -49 th percentile 50th-74 th percentile >75 th percentile p-value OR (95%CI) OR (95 t% CI) OR (95 % CI) IL-6 (inflammation) ( ) 3.2 ( ) 8.3 ( ) < D-dimer (coagulation) ( ) 4.0 ( ) 12.4 ( ) < Kuller L, et al. PLoS Med 2008

Untreated HIV infection and CVD pathogenesis: a proposed model Baker J and Lundgren J. Eur Heart J 2011

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Cardiovascular complications of HIV ART and myocardial infarction Friis-Moller N, et al. D:A:D. NEJM MI incidence according to duration of ART exposure

MI risk disease by ARV exposure in D:A:D Worm S, et al. D:A:D. JID ART exposure and MI risk in D:A:D Cardiovascular complications of HIV

Untreated HIV infection and CVD pathogenesis: a proposed model Baker J and Lundgren J. Eur Heart J 2011

Treated HIV infection and CVD pathogenesis: a proposed model Baker J and Lundgren Eur Heart J ART Insulin resistance

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Myocardial Infarction Never smoked Previous Baseline status < 1 yr1-2 yrs2-3 yrs3+ yrsCurrent Stopped smoking during follow-up Adjusted for: age, sex, cohort, calendar year, antiretroviral treatment, family history of CVD, diabetes, and time-updated lipids and blood pressure assessments D:A:D study group. HIV Med Stop Smoking

Cardiovascular disease in HIV Prevention: monitor and modify risks Petoumenos K for D:A:D. 20 th CROI Reduce TC 1 mmol/L Stop smoking CVD hazard in D:A:D* Reduce sysBP 10 mmHg *relative to 40 y.o. HIV+ male

Control dyslipidaemia: use TDF TDF (n=170) d4T (n=162) p-value Total-cholesterol (mmol/L) <0.001 HDL-cholesterol (mmol/L) LCL-cholesterol (mmol/L) <0.001 TG (mmol/L) <0.001 Total limb fat gain-DXA (kg) <0.001 Total weight gain (kg) Neuropathy3%10%<0.001 Gallant J, et al. GS 934 study. JAMA 2004;292:

CVD complications of HIV Ahmed H et al. MESA. Am J Epi Prevention: adopt a healthy lifestyle Probability of CHD according to health score Score 0 Score 2 Score 3 & 4

CVD complications of HIV Ahmed A, et al. MESA. Am J Epi Prevention: adopt a healthy lifestyle Probability of death according to health score Score 3 & 4 Score 2 Score 1 Score 0

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

CVD complications of HIV: key messages Walker S, et al. DART. Lancet ART saves lives

CVD complications of HIV: key messages 3 year riskOff ARTOn ART AIDS/Death %6 - 11% AMI0.3% ( ) 1% ( ) Law M et al. HIV Med The risk of death from AMI is much less than the risk of dying from untreated HIV-infection

CVD complications of HIV: key messages Monitor and treat modifiable risk factors Stop smoking Monitor& treat hypertension Monitor & treat dyslipidaemia and diabetes Encourage healthy weight, diet and exercise Monitor and treat HIV-infection –according to guidelines –there is no evidence to support use of specific ART regimens for PLHIV with high-risk for CVD

Cardiovascular Complications Outline Epidemiology Risk factors –host –virus-host –ART Prevention Key messages Conclusions

Cardiovascular Complications of HIV Conclusions Cardiovascular disease pathogenesis in HIV is complex While HIV factors may add to complexity, conventional risk factors are prominent Risks can be monitored and modified Primary prevention is key in low-, middle- and high-income settings